$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

2018-03-31

2022-05-31

2022-05-31

151

Study Overview

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy

Research hypothesis: Patients profit from 2nd-line therapy with Nal-IRI if they also had a benefit from 1st-line treatment. Benefit from treatment (either 1st or 2nd-line) will be defined as a patient specific Time-To-Treatment Failure (TTF) which is in the upper third of the distribution of TTF values of the studied population.

  • Locally Advanced Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • DRUG: Irinotecan Liposomal Injection [Onivyde]
  • AIO-PAK-0216

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2018-01-19  

N/A  

2025-04-15  

2018-03-15  

N/A  

2025-04-17  

2018-03-16  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
OTHER: Single Arm

Cancer treatment for PDAC: * Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion * 5-FU 2400 mg/m2 as 46 hour infusion * Folinic acid 400 mg/m2 as 0.5 hour infusion * all on D1 of each cycle; Cycle q2w ± 5 days Treatment until progressive disease or intol

DRUG: Irinotecan Liposomal Injection [Onivyde]

  • Cancer treatment for PDAC: * Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion * 5-FU 2400 mg/m2 as 46 hour infusion * Folinic acid 400 mg/m2 as 0.5 hour infusion * all on D1 of each cycle; Cycle q2w ± 5 days Treatment until progressive disease or intol
Primary Outcome MeasuresMeasure DescriptionTime Frame
Time to Treatment Failure of second-line treatment (TTF2)Time-To-Treatment-Failure - (TTF2) is defined as date of signed ICF until permanent treatment discontinuation (or day of initially planned next cycle) due to progressive disease or unacceptable toxicity. Expected increase of the TTF2 by 50% in the cohort of patients with favorable TTF1 (TTF1 high: upper third of the patient population) as compared to patients with short TTF1 (TTF low: lowest third of the patient population)up to 6 month
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Overall survival (OS)Survival will be calculated from the date ICF signature until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.up to 12 month
Progression Free Survival (PFS)PFS is defined as the number of months from the date of first dose of 2nd-line treatment to the date of death or investigator assessed progression (by any imaging techique), whichever occurred earlier. If neither death nor progression is observed during the study, PFS data will be censored at the last valid tumor assessment.up to 12 month
AEs / SAEsThe Safety Population is the primary population for the evaluation of treatment administration/compliance and all safety data and will comprise all patients enrolled who received at least one dose of study medication. Patients will be analyzed according to the treatment actually received.up to 12 month
Quality of Life (QoL) EORTC QLQ-C30Helath related Quality of Life will be evaluated with: - EORTC QLQ-C30up to 6 month
Quality of Life (QoL) EORTC QLQ-PAN26Helath related Quality of Life will be evaluated with: - EORTC QLQ-PAN26up to 6 month
Quality of Life (QoL) EORTC EQ-5D-5LHelath related Quality of Life will be evaluated with: - EORTC EQ-5D-5Lup to 6 month
Evaluation of time to definitive deterioration of QoL (TDD)Time to QoL deterioration is defined as a loss of ≥ 10 points in the EORTC QLQ-C30 compared to base-line.from date of baseline Scrore until date QoL Score deterioration, assessed up to 12 month
Growth modulation index (GMI)The ratio of time to progression with the nth-line (TTP(n)) of therapy to the TTP(n-1) with the n-1th-line. GMI >1.33 is considered as a sign of activity in phase II trials.up to 6 month

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Written informed consent including participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations 2. Clinical indication for a 2nd-line systemic therapy according to current standard-of-care. 3. Age ≥ 18 years at time of study entry 4. Patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma 5. Imaging of evaluable lesions within 2 weeks of inclusion (either sonography, X-ray, CT scans, MRI) 6. ECOG performance status 0-2 7. One line of systemic gemcitabine/Nab-paclitaxel -based therapy for advanced disease (irrespective of prior adjuvant therapy) OR Previous adjuvant gemcitabine/Nab-paclitaxel-based chemotherapy with documented progression less than 6 months after termination 8. Detailed documentation of prior therapy (duration, dose-intensity, maximum toxicity, reason for discontinuation) 9. Adequate blood count, liver-enzymes, and renal function:

  • neutrophil count > 1.5 x 10^6/mL
  • Platelet count ≥ 100 x 10^9/L (≥100,000 per mm^3)
  • AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
  • bilirubin ≤1.5 ULN (<3 x ULN in patients with confirmed mechanical cholestasis)
  • Creatinine Clearance CLcr ≥ 30 mL/min 10. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

    • Exclusion Criteria:
    Medical criteria:
    1. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:
    1. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes 2. Premalignant hematologic disorders, e.g. myelodysplastic syndrome 3. Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment 4. Prior (<3 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial urinary bladder tumor [Ta, Tis and T1]. 5. Pre-existing lung disease of clinical significance or with impact on performance status 6. History or clinical evidence of CNS metastases
    Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
    I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of study treament. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases 7. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy 8. Severe non-healing wounds, ulcers or bone fractions 9. Evidence of bleeding diathesis or coagulopathy 10. Major surgical procedures, except open biopsy, or significant traumatic injury within 28 days prior to star of study treatment, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration. 11. Known Gilbert-Meulengracht syndrome 12. Known chronic hypoacusis, tinnitus or vertigo 13. Bone marrow depression (e.g., after radiation therapy) 14. Pernicious anemia and other megaloblastic anemias secondary to vitamin B12 deficiency 15. Severe impairment of hepatic function 16. Diarrhea
    Drug related criteria: 2. Medication that is known to interfere with any of the agents applied in the trial. 3. Known dihydropyrimidine dehydrogenase (DPD) deficiency 4. History of hypersensitivity to any of the study drugs or any of the constituents of the products. 5. Any other efficacious cancer treatment except protocol specified treatment at study start.
    Safety criteria: 6. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (urine or serum β-HCG acc. to SOC) at Screening.
    Methodological criteria: 7. Any experimental pretreatment for advanced disease 8. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is longer. 9. Previous enrollment in the present study (does not include screening failure).
    Regulatory and ethical criteria: 10. Patient who might be dependent on the sponsor, site or the investigator 11. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • Crolll Gmbh
  • Servier Deutschland GmbH
  • PRINCIPAL_INVESTIGATOR: Manfred P. Lutz, Prof. Dr., m.lutz@caritasklinikum.de

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Treat yourself

Let Us Take Care Of You

BOOK AN APPOINTMENT ⟶
footer logo

About

Events

Fundraising

Contact Us

Facebook-f Instagram

NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate